NCT01731990View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 30, 2012

Primary Completion Date

August 4, 2016

Study Completion Date

August 4, 2016

Conditions
Peripheral Artery Disease
Interventions
DRUG

Canakinumab (ACZ885)

Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use.

DRUG

Placebo

Matching placebo of Canakinumab

Trial Locations (14)

11941

Novartis Investigative Site, Amman

20099

Novartis Investigative Site, Hamburg

21093

Novartis Investigative Site, Lutherville

22559

Novartis Investigative Site, Hamburg

23294

Novartis Investigative Site, Richmond

32207

Novartis Investigative Site, Jacksonville

32216

Novartis Investigative Site, Jacksonville

37920

Novartis Investigative Site, Knoxville

43215

Novartis Investigative Site, Columbus

55116

Novartis Investigative Site, Mainz

60611

Novartis Investigative Site, Chicago

69120

Novartis Investigative Site, Heidelberg

80336

Novartis Investigative Site, München

85302

Novartis Investigative Site, Phoenix

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY